New insider activity at Sol-Gel Technologies ( (SLGL) ) has taken place on July 10, 2026.

Opaleye Management Inc., a significant shareholder in Sol-Gel Technologies, has increased its stake by purchasing 529 shares of the company’s stock. This latest transaction, valued at $39,041, underscores Opaleye’s continued confidence in Sol-Gel Technologies and adds to the institutional interest surrounding the stock.

Sol-Gel Technologies saw fresh analyst attention in the last 24 hours as Mizuho initiated coverage, attributing its positive stance mainly to SGT-610’s potential as a first-in-class FDA-approved therapy to prevent new basal cell carcinoma lesions in Gorlin syndrome. The firm emphasized the drug’s validated mechanism, existing off-label systemic hedgehog inhibitor use, and a perceived underappreciation of Sol-Gel’s Gorlin opportunity at current share levels, which together underpinned the revised outlook and supported recent stock strength.